KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Cash & Equivalents (2016 - 2025)

Cardlytics (CDLX) has disclosed Cash & Equivalents for 10 consecutive years, with $48.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 25.73% year-over-year to $48.7 million, compared with a TTM value of $48.7 million through Dec 2025, down 25.73%, and an annual FY2025 reading of $48.7 million, down 25.73% over the prior year.
  • Cash & Equivalents was $48.7 million for Q4 2025 at Cardlytics, up from $44.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $613.5 million in Q1 2021 and bottomed at $44.0 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $143.3 million, with a median of $94.9 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 500.49% in 2021, then tumbled 66.05% in 2022.
  • Year by year, Cash & Equivalents stood at $233.5 million in 2021, then plummeted by 47.78% to $121.9 million in 2022, then decreased by 24.67% to $91.8 million in 2023, then fell by 28.57% to $65.6 million in 2024, then decreased by 25.73% to $48.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for CDLX at $48.7 million in Q4 2025, $44.0 million in Q3 2025, and $46.7 million in Q2 2025.